DHT, Testosterone, and the Prostate: Why It's More Complicated Than 'More T Is Better'

One of the more confused topics in middle-aged men's health is the relationship between testosterone, DHT, and the prostate. The marketing space is full of opposing claims: testosterone "boosters" promising vitality, DHT-blockers promising hair preservation and prostate health, and a general implication that all of this is downstream of a single "more testosterone = more masculine = better" narrative.

It's more complicated, and the complications matter.

Two hormones, not one

Testosterone and DHT (dihydrotestosterone) are related but distinct hormones with different actions:

• Testosterone is the headline male hormone — produced primarily in the testes, responsible for muscle mass, libido, mood, energy, and a wide range of systemic effects.
• DHT is a metabolite of testosterone, formed when an enzyme called 5-alpha-reductase converts testosterone to DHT in specific tissues. DHT is far more potent than testosterone at the androgen receptor in those tissues.

The tissues where 5-alpha-reductase is most active include the prostate, the scalp hair follicles, and to a lesser degree the skin. This is why DHT has tissue-specific effects — it's high where the enzyme is high.

The good and the bad of DHT

DHT isn't villainous; it's necessary. In adolescence, DHT drives the development of male secondary sexual characteristics. In adulthood, it contributes to libido and to the maintenance of various male tissues.

But in two specific contexts, DHT works against you:

1. The prostate. Lifetime DHT exposure is the primary driver of benign prostatic hyperplasia. The men who happen to be genetically deficient in 5-alpha-reductase (a real and well-characterised condition) almost never develop BPH or male-pattern baldness.
2. Scalp hair follicles. DHT-sensitive follicles miniaturise progressively, producing male-pattern hair loss.

For most men in midlife, the question becomes: how do we maintain healthy testosterone (which has overwhelmingly positive effects systemically) while moderating DHT exposure to the prostate (which has predominantly negative effects there)?

The interventions, layered

1. Pharmaceutical 5-ARI inhibitors

Finasteride and dutasteride are the prescription drugs that block 5-alpha-reductase. They're highly effective at reducing DHT systemically (60-90% reduction depending on the drug). They reliably shrink the prostate over months and reduce BPH symptoms substantially.

The cost: meaningful side effects in some men, including sexual side effects (reduced libido, erectile changes) that can sometimes persist after discontinuation. The "post-finasteride syndrome" literature is real but contested in its severity. For men with severe BPH, the trade-off can be worth it. For men with mild BPH, it often isn't.

2. Saw Palmetto and the botanical layer

Saw Palmetto modestly inhibits 5-alpha-reductase activity in prostate tissue specifically — far less potently than finasteride, and with a much milder side-effect profile. The effect on systemic testosterone is minimal; the effect on prostate-tissue DHT is meaningful over time.

This is a more proportionate intervention for mild-to-moderate BPH: real DHT modulation where you want it (the prostate), without the systemic disruption.

3. Lifestyle factors that affect DHT

Some lifestyle factors modestly affect DHT:

• Visceral fat reduction lowers aromatase activity (which is upstream of various androgen-related issues).
• Adequate zinc status supports healthy 5-alpha-reductase regulation.
• Some plant-derived sterols (beta-sitosterol, present in pumpkin seeds and similar foods) modestly affect DHT metabolism.

Effect sizes here are small; they're worth knowing about but not worth obsessing over.

Where this leaves men trying to optimise

For most men in their fifties dealing with early BPH or strong family history of it:

• Maintain healthy testosterone via the standard levers (sleep, training, body composition, addressing deficiencies).
• Apply moderate DHT modulation specifically to prostate tissue via Saw Palmetto and similar.
• Accept that some level of DHT exposure to the prostate is the cost of having functioning testosterone systemically — the trade-off isn't avoidable, only manageable.
• Reserve pharmaceutical 5-ARIs for cases where the symptoms have become severe enough to justify the side-effect profile.

The honest summary

Testosterone and DHT aren't simple. The "more is better" narrative misses the tissue-specific reality — that the same hormonal pathway has different effects in different tissues, and that modulating it well requires nuance. For most middle-aged men, the goal isn't to drive testosterone as high as possible or to eliminate DHT entirely. It's to maintain healthy hormone levels systemically while keeping prostate-tissue DHT exposure within ranges that don't accelerate BPH unnecessarily.

The botanical layer does this well. The pharmaceutical layer does it dramatically but with cost. The lifestyle layer does it modestly. They stack.